)
Edge14 Aug 2026
Deutsche Qualität: The Story of Birkenstock
From an 18th-century German shoemaker to a global footwear brand, how Birkenstock turned an orthopedic insole into the world's most popular sandal.
Neumora Therapeutics
Neumora Therapeutics (NMRA) investor relations material
Neumora Therapeutics Company presentation summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Company presentation summary14 Aug, 2026
Mission and leadership
Focused on developing next-generation, brain-penetrant therapies to improve outcomes and quality of life for patients with neurological and psychiatric disorders.
Led by experienced executives and board members with backgrounds in major pharmaceutical and biotech companies.
Strategic focus and market opportunity
Targeting large unmet needs in neuropsychiatric, neurodegenerative, and cardiometabolic diseases, which impact millions in the U.S.
Programs aim to provide novel mechanisms, improved tolerability, and oral treatment options for these conditions.
Pipeline and clinical development
Advancing three main franchises: NMRA-215 (obesity/cardiometabolic), NMRA-511 (Alzheimer’s agitation), and NMRA-898 (schizophrenia).
NMRA-215: Differentiated NLRP3 inhibitor showing class-leading weight loss, improved metabolic biomarkers, and potential for combination therapy with semaglutide.
NMRA-511: V1aR antagonist with strong efficacy and safety in Alzheimer’s agitation, especially in patients with elevated anxiety.
NMRA-898: M4 muscarinic receptor PAM for schizophrenia, optimized for CNS exposure and potency, with promising Phase 1 results.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Neumora Therapeutics
- Net loss narrowed, cash runway extends into Q3 2027, but going concern risk persists.NMRA
Q2 2026 - Advancing differentiated CNS therapies with strong efficacy and safety toward late-2026 milestones.NMRACorporate presentation
- Navacaprant's phase III COASTAL Program targets MDD and anhedonia, with pivotal data expected Q4.NMRAStatus Update
- Lead programs show strong efficacy and safety, with key clinical milestones expected in 2026.NMRAInvestor presentation
- Directors re-elected, auditor ratified, and annual executive pay votes approved.NMRAAGM 2026
- Navacaprant, NMRA-511, NMRA-215, and NMRA-898 advance with key data readouts and clinical milestones ahead.NMRARBC Capital Markets Global Healthcare Conference 2026
- Net loss narrowed to $53.5M as cash runway extends into Q3 2027 and pipeline advances.NMRAQ1 2026
- NMRA-215 showed up to 26% preclinical weight loss; multiple clinical catalysts expected in 2026.NMRAR&D Day 2025
- Pivotal Phase 3 MDD data expected year-end, with $341.3M cash runway into mid-2026.NMRAQ3 2024
Next Neumora Therapeutics earnings date
Q3 20266 Nov, 2026
Neumora Therapeutics
Next Neumora Therapeutics earnings date
Q3 20266 Nov, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage